Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), has announced a licensing opportunity for pDNA manufacturing. The Keystone Expression System pDNA platform is an end-to-end solution for manufacturing GMP pDNA at scale in a manufacturer’s own facility.
 
“This is a great opportunity for biologics manufacturers to reduce the time and cost of getting their pDNA products to market through the use of our perfected manufacturing process,” said Matt Delaney, vice president of business development and marketing, Cytovance. “Our platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high-quality, high-yield pDNA.”
 
License opportunities are currently available for either a 30L or 300L manufacturing scale. Each license includes end-to-end documentation including process descriptions, analytical standard operating procedures, critical equipment lists, facility layout, and much more. To ensure that pDNA manufacturing can begin quickly, Cytovance also offers hands-on process training, with our experts, at the manufacturer’s facility.